Enliven Therapeutics Inc [ELVN] stock is trading at $20.74, down -2.95%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ELVN shares have gain 16.71% over the last week, with a monthly amount glided 13.52%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on December 13, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $42. Previously, H.C. Wainwright started tracking the stock with Buy rating on September 09, 2024, and set its price target to $37. On June 11, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $32 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $34 on April 09, 2024. Jefferies initiated its recommendation with a Buy and recommended $27 as its price target on March 29, 2023.
Enliven Therapeutics Inc [ELVN] stock has fluctuated between $13.30 and $30.03 over the past year. Currently, Wall Street analysts expect the stock to reach $39 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $20.74 at the most recent close of the market. An investor can expect a potential return of 88.04% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.68 points at the first support level, and at 18.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.16, and for the 2nd resistance point, it is at 23.59.
Ratios To Look Out For
For context, Enliven Therapeutics Inc’s Current Ratio is 21.06. Further, the Quick Ratio stands at 21.06, while the Cash Ratio is 7.28.
Transactions by insiders
Recent insider trading involved Lyssikatos Joseph P, CHIEF SCIENTIFIC OFFICER, that happened on Jun 03 ’25 when 7500.0 shares were sold. PRESIDENT AND CEO, Kintz Samuel completed a deal on Jun 03 ’25 to sell 7500.0 shares. Meanwhile, Officer Kintz Samuel bought 7500.0 shares on Jun 03 ’25.
